Discovery of a Novel HSP90-Targeting Inhibitor for AML from the Marine Aaptamine Scaffold
Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 19107-19129
DOI: 10.1021/acs.jmedchem.6c01410 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 28.07.2026. Verfasst von Haitao Xue und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Ren Ji Hospital, College of Clinical Pharmacy, State Key Laboratory of Microbial Metabolism, Shanghai Jiao Tong University Sc…. Hauptthemen laut MEDLINE: HSP90 Heat-Shock Proteins, Leukemia, Myeloid, Acute, Antineoplastic Agents. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Innovative Research Team of High-level Local University in Shanghai, National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Resistance to single-target therapies has spurred interest in multitarget strategies for acute myeloid leukemia (AML). Heat shock protein 90 (HSP90), a chaperone that stabilizes numerous oncogenic client proteins, represents an attractive therapeutic target for AML; however, the clinical development of early HSP90 inhibitors was limited by dose-limiting toxicities and an excessive heat-shock response (HSR). Through structural optimization of the marine aaptamine scaffold and target identification, ap-a48 was identified as a novel HSP90-targeting anti-AML lead that exhibits potent anti-AML activity and acceptable preliminary tolerability while inducing only a modest HSR. In rats, ap-a48 showed favorable pharmacokinetics with 65.3% oral bioavailability, and in HL-60 xenograft mouse models, it suppressed tumor growth (71.2% inhibition at intraperitoneal 40 mg/kg; 67.3% at oral 60 mg/kg) without significant hepatotoxicity or major organ abnormalities. These findings identify ap-a48 as a promising marine-natural-product-derived HSP90-targeting lead for AML therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Ren Ji Hospital, College of Clinical Pharmacy, State Key Laboratory of Microbial Metabolism, Shanghai Jiao Tong University School of Medicine, Shanghai200127, China.
- School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai200240, China.
- School of Food and Drug-Institute of Marine Biomedicine, Shenzhen Polytechnic University, Shenzhen518000, China.
- Integrated Innovation Center for Marine Drugs, Shanghai Jiao Tong University, Shanghai200240, China.
- Marine Biomedical Science and Technology Innovation Platform of Lin-gang Special Area, Shanghai201306, China.
ORCID-Profile: Bin Cheng, Hongze Liao, Houwen Lin
Förderung
- Innovative Research Team of High-level Local University in Shanghai
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- Natural Science Foundation of Shandong Province
- National Key Research and Development Program of China
- Lingang Special Area Marine Biomedical Innovation Platform
Zitieren
APA
Xue, H., Zhu, H., Liu, S., Qian, Y., Cheng, B., Sun, F., Liao, H., & Lin, H. (2026). Discovery of a Novel HSP90-Targeting Inhibitor for AML from the Marine Aaptamine Scaffold. Journal of Medicinal Chemistry, 69(15), 19107-19129. https://doi.org/10.1021/acs.jmedchem.6c01410
Vancouver
Xue H, Zhu H, Liu S, Qian Y, Cheng B, Sun F, et al. Discovery of a Novel HSP90-Targeting Inhibitor for AML from the Marine Aaptamine Scaffold. Journal of Medicinal Chemistry. 2026;69(15):19107-19129. doi:10.1021/acs.jmedchem.6c01410
BibTeX
@article{Xue2026,
author = {Xue, Haitao and Zhu, Hongrui and Liu, Shuai and Qian, Yongtao and Cheng, Bin and Sun, Fan and Liao, Hongze and Lin, Houwen},
title = {Discovery of a Novel HSP90-Targeting Inhibitor for AML from the Marine Aaptamine Scaffold},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {15},
pages = {19107--19129},
doi = {10.1021/acs.jmedchem.6c01410}
}
EUVIMED